Can-Fite Shares Rally After Compassionate-Use Patient Stabilized and Transplanted Following Namodenoson Treatment
Can-Fite BioPharma's stock climbed 9.5% after the company reported that a patient with advanced decompensated liver cirrhosis treated with Namodenoson under compassionate use achieved sufficient clinical stabilization to proceed to a successful liver transplant once a donor became available. The company highlighted the case while Namodenoson contin…